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Abstract
Background: We sought to investigate the relationships among the plasma levels of carotenoids, tocopherols,
endogenous antioxidants, oxidative damage and lipid profiles and their possible effects on the cardiovascular risk
associated with hemodialysis (HD) patients.
Methods: The study groups were divided into HD and healthy subjects. Plasma carotenoid, tocopherol and
malondialdehyde (MDA) levels, as well as erythrocyte reduced glutathione (GSH), were measured by HPLC. Blood
antioxidant enzymes, kidney function biomarkers and the lipid profiles were analyzed by spectrophotometric
methods.
Results: Plasma lycopene levels and blood glutathione peroxidase (GPx) activity were significantly decreased in HD
patients compared with healthy subjects. Total cholesterol, low-density lipoprotein cholesterol (LDL-c), creatinine,
urea, MDA, GSH, superoxide dismutase (SOD) and catalase (CAT) were significantly increased in HD (p < 0.05).
Lycopene levels were correlated with MDA (r = -0.50; p < 0.01), LDL-c (r = -0.38; p = 0.01) levels, the LDL-c/HDL-c
index (r = -0.33; p = 0.03) and GPx activity (r = 0.30; p = 0.03). Regression models showed that lycopene levels
were correlated with LDL-c (b estimated = -31.59; p = 0.04), while gender was correlated with the TC/HDL-c index
and triglycerides. Age did not present a correlation with the parameters evaluated. GPx activity was negatively
correlated with MDA levels and with the LDL-c/HDL-c and CT/HDL-c indexes.
Conclusions: Lycopene may represent an additional factor that contributes to reduced lipid peroxidation and
atherogenesis in hemodialysis patients.
Background
In chronic renal failure (CRF) patients undergoing hemo-
dialysis (HD) treatment, the formation of reactive oxygen
species (ROS) is amplified, and oxidative stress may be
one of the most relevant complications [1]. The increase
in ROS is due to uremic toxins, bio-incompatible dialysis
water, non-sterile dialysate, poor quality of dialysis water,
back-leak of contaminants across the dialysis membrane
and time of hemodialysis treatment [2,3].
In hemodialysis patients (HD), the major cause of death
is cardiovascular disease, which is responsible for 50% of
the mortality in this population [4,5]. The physiopathol-
ogy of cardiovascular events in HD is multifactorial, but
accelerated atherosclerosis seems to play a central role in
cardiovascular dysfunction. In addition, current evidence
suggests that the high prevalence of cardiovascular events
in these patients is directly linked to oxidative stress and
to the abnormality of the plasma lipid profile [6-10].
The abnormalities in the antioxidant defense system
and increased oxidative stress may lead to higher sus-
ceptibility to lipid peroxidation of low density lipoprotein
(LDL) [2,3,11]. Antioxidant vitamins and dietary consti-
tuents (for example, vitamin C, tocopherols, a-carotene
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protection against oxidative damage and, consequently,
against atherosclerosis [12-14].
Although there are published studies that have evalu-
ated biochemical alterations, endogenous antioxidants
and vitamins in HD patients [15], there is lack of infor-
mation about the relationships among oxidative stress
biomarkers, vitamins and classical biochemical altera-
tions. Therefore, the aim of this cross-sectional study was
to evaluate whether exogenous and/or endogenous anti-
oxidants may affect lipid peroxidation, cholesterol or
cholesterol lipoproteins, which are important biomarkers
involved in atherosclerosis in HD patients. Exogenous
antioxidants, such as carotenoids (lycopene, lutein, zeax-
anthin, a-a n db-carotene, b-cryptoxanthin), vitamin E
(a-a n dg-tocopherol), and endogenous antioxidants
( G S H ,S O D ,G P xa n dC A T ) ,a l o n gw i t ht h es e r u ml i p i d
profile, lipid peroxidation biomarkers, and markers of
serum kidney function, were evaluated.
Methods
Subjects
The study was approved by the Human Ethics Commit-
tee of the Science Health Center of the Federal University
of Santa Maria (protocol number 091/2003). All patients
gave their informed consent prior to inclusion in the
study. The study included twenty-nine patients diagnosed
with CRF (19 men and 10 women) and submitted to reg-
ular hemodialysis treatment at Charity and Health House
Hospitals. Additionally, 20 healthy subjects, including 10
men and 10 woman (control group), were enrolled. In
order to participate in this research, patients were
required to have been receiving regular hemodialysis
treatment. Only non-smokers who were free of any pro-
blems related to alcoholism, viral hepatitis and HIV were
included in the study. Patients using any antioxidant vita-
min within the last three months were also excluded.
The control group did not have clinical histories of renal
diseases or other pathologies. None of the healthy sub-
jects received vitamins. The subjects were all non-smo-
kers and did not consume alcohol regularly.
For the sampling, 10 ml of venous blood was collected
from the HD patients before the hemodialysis process
(two days after the last process) under conditions of fast-
ing. Blood was also collected from the subjects in the
control group. The analysis samples were divided into
heparinized tubes, EDTA-containing tubes, and tubes
without anticoagulant. Plasma-EDTA and serum were
obtained by centrifugation at 1500 g for 10 minutes at 4°C.
The plasma samples were used to evaluate carotenoids
and tocopherols. To assess the antioxidant enzymes, blood
samples were stored at -20°C until analysis. Plasma malon-
dialdehyde (MDA) and erythrocyte reduced glutathione
(GSH) were processed immediately followed by the
determination of hemoglobin (Hb) levels and hematocrit
(Hct) in the blood, as well as albumin, iron, ferritin, cho-
lesterol, triglycerides, urea and creatinine levels in the
serum.
The quantification of plasma carotenoids (lutein, zeax-
anthin, lycopene, b-cryptoxanthin, a-a n db-carotene) and
tocopherols (a and δ-tocopherol) was carried out after
liquid-liquid extraction with a solution of n-butanol:etha-
nol (50:50) in BHT (2,6-di-ter-butyl-4-methylphenol)
mixed by vortexing and followed by centrifugation. The
supernatant was analyzed by high performance liquid
chromatography (HPLC) with a UV/VIS and fluorescent
detector according to Epler et al., 1993 [16] with modifica-
tions. The b- apo - 8 carotene was used as an internal
standard.
Hemoglobin levels and hematocrit were determined in
a Cobas Micros system (Hematology Analyzer, Roche
Diagnostics
®). The biochemistry analyses consisted of
albumin, iron, ferritin, serum total cholesterol (TC),
lower-density lipoprotein cholesterol (LDL-c), high-den-
sity lipoprotein cholesterol (HDL-c), triglycerides, urea
and creatinine, which were determined using the Cobas
Integra 400 (Roche Diagnostics
®) automatic device and
commercial kits. The indexes of coronary risk were
obtained through the following calculations: TC/HDL-c
and LDL-c/HDL-c.
Lipid peroxidation was estimated by the measurement
of plasmatic malondialdehyde, which was determined by
a high performance liquid chromato-graphic system
with visible detection (HPLC-VIS) by Knauer
® using a
method developed in our laboratory [17].
The levels of reduced glutathione in erythrocytes were
measured by high performance liquid chromatography
with the Knauer
® system using a method developed in
our laboratory [18].
Enzyme assays were performed in total blood with
heparin. Superoxide dismutase (SOD) activity was deter-
mined at 480 nm based on its ability to inhibit the autoxi-
dation of adrenaline into adrenochrome at an alkaline pH
[19]. Catalase (CAT) activity was determined at 280 nm
using H2O2 as substrate [20]. Glutathione peroxidase
(GPx) activity was determined using glutathione reductase
a n dN A D P H .T h em e t h o di sb a s e do nt h eo x i d a t i o no f
NADPH, which is measured by a decrease in absorbance
at 340 nm [21]. These activities were measured spectro-
photometrically using a UV-VIS model Hitachi U-1800
®.
Statistical analysis
Statistical computations were performed with the Statis-
tica
® 6.0 software system (Statsoft Inc., 2001). The results
are expressed as the mean ± SEM (standard error of the
mean). Comparisons between groups were achieved by
Student’s t-test or the Mann-Whitney test depending on
the distribution of the variables. Pearson’s or Spearman’s
Roehrs et al. BMC Nephrology 2011, 12:59
http://www.biomedcentral.com/1471-2369/12/59
Page 2 of 9rank order linear correlation was used to evaluate the
relationships between pairs of variables according to
their distribution. Multivariate regression analyses were
performed with Jump 5.0.1a (SAS Institute Inc., Cary,
NC, USA) to evaluate antioxidants with significant pro-
tective effects on the lipid profile (triglycerides, total cho-
lesterol, LDL-c and HDL-c, as well as the LDL-c/HDL-c
and TC/HDL-c indexes) and lipid peroxidation. More-
over, the possible influences of age and gender were eval-
uated, and p < 0.05 (5%) was considered significant.
Results
The mean length of hemodialysis treatment in the HD
patient group was 45.68 ± 7.27 months. The age of the
HD patients was significantly higher than that of the con-
trol group’s patients (51.0 ± 2.17 and 43.15 ± 1.30 years
(SEM), respectively). However, after regression analysis
(Table 1), it was found that age did not have a significant
influence on the parameters evaluated.
T h ec l i n i c a lh i s t o r i e so ft h eH Dp a t i e n t sw e r ee v a l u -
ated, and the causes of renal failure were pyelonephritis
and glomerulonephritis (n = 6 or 17.2% of the patients),
hypertension (n = 3 or 10.3% of the patients), diabetes
(n = 3 or 10.3% of the patients), polycystic kidney disease
(n = 1 or 3.5% of the patients), tuberculosis of the urinary
tract (n = 2 or 7% of the patients), and, in 37.9% of the
patients (n = 11), there was no known cause.
With respect to the therapeutic treatment of the HD
patients, it was observed that just six patients received
vitamin D, while seventeen patients received erythro-
poietin, and eleven of those patients also received nori-
purum (saccharate ferric hydroxide). Moreover, statins
were used for reducing lipid levels, and none of the
patients received nutritional supplementation or a multi-
vitamin complex. The treatments were chosen and
changed by clinicians based on constant monitoring of
the laboratorial results and clinical observations.
Serum levels of iron and ferritin in HD patients were
53.04 ± 3.69 mg.dL
-1 and 347.84 ± 72.40 ng.mL
-1
(SEM), respectively. These values were consistent with
the reference values. Additionally, other hematological
and biochemical analyses were performed monthly, and
the results are presented in T a b l e s2a n d3( r e f e r e n c e
values are also presented). Hematocrit, hemoglobin
levels and albumin levels were lower in HD patients
than in the control group, and they were below of the
reference values. Biomarkers of renal function, including
creatinine and urea, were significantly higher in HD
patients and were above the reference values. Moreover,
correlations between serum creatinine levels and GPx
activity (r = -0.67; p < 0.01), as well as serum urea levels
and GPx activity (r = -0.77; p < 0.01), were found.
The analysis of the lipid profile included total choles-
terol (TC), LDL-c, HDL-c, triglycerides and the indexes
of coronary risk (ICR), and the results are presented in
the Table 3. The results are sub-grouped by gender
within each group of study. In the control group, no dif-
ference was observed among the lipid profiles when
comparing women vs. men. In the HD group, the trigly-
cerides were significantly higher in men compared to
women.
The levels of total cholesterol, LDL-c and triglycerides
are within the reference values for both groups studied.
However, the Mann-Whitney test revealed that these vari-
ables were significantly higher in the HD group compared
with the control group. On the other hand, the HDL-c
was below the reference values in HD patients, and it was
also significantly decreased compared with the control
group. The TC/HDL-c index was twice higher in HD
compared to healthy subjects, and the LDL-c/HDL-c
index was three times higher. Moreover, in the regression
analysis, it was found that gender presented an influence
on the TC/HDL index (b estimated = 1.05; p = 0.04) and
triglyceride levels (b estimated = 17.82; p = 0.03).
Additionally, the clinical history of the HD group was
evaluated for two years after the collection of the blood
samples. Seven deaths occurred (24.1% of the total) in
this period, and cardiovascular diseases (n = 6; 85.7%)
was the main cause of death; only one of these deaths
(3.5%) was due to a stroke. However, the Mann-Whitney
test did not show statistically significant differences
among any of the parameters analyzed between the HD
patients that died (n = 7) during the present study and
those that survived (n = 22). This lack of significant dif-
ference may be related to the small number of individuals
in the group that died during the study.
The results of our analyses of the oxidative stress bio-
markers are presented in Table 4. The plasma MDA and
erythrocyte GSH levels were significantly increased in the
HD patients compared to healthy subjects (p < 0.01).
The blood SOD and CAT activities were significantly
increased (p < 0.05), while GPx activity was significantly
d e c r e a s e d( p<0 . 0 1 )i nH Dp a t i e n t sc o m p a r e dw i t ht h e
control group. Moreover, in the control group, SOD,
CAT and GPx activities were similar between women
and men. On the other hand, the CAT activity was influ-
enced by gender in the HD group, as it was higher in
women than men. The results of the Mann-Whitney test
showed that gender had a significant effect on some of
the parameters evaluated (Tables 2 to 5). However, only
the TC/HDL-c index and triglyceride levels were influ-
enced by gender in regression models (Table 1).
The non-enzymatic and enzymatic endogenous antioxi-
dants listed above were linearly associated the hematocrit
and hemoglobin levels, as well as urea and creatinine levels
(data no shown). In addition to these correlations, the lipid
profile also presented linear associations with endogenous
antioxidants (p < 0.05). GSH was significantly associated
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Page 3 of 9Table 1 Regression analysis realized to lipid peroxidation, lipid profile and antioxidants.
LDL-c (R
2) of model: 0.14 HDL-c (R
2) of model: 0.67 MDA (R
2) of model:
0.47
TC/HDL (R
2) of model: 0.53 LDL/HDL (R
2) of model: 0.60 TG (R
2) of model: 0.51
b coeff p b coeff p b coeff p b coeff p b coeff p b coeff p
Age ns 0.75 ns 0.11 ns 0.10 ns 0.08 ns 0.33 ns 0.35
Gender ns 0.66 ns 0.11 ns 0.08 1.05 0.04 ns 0.10 17.82 0.03
SOD ne - ns 0.69 ns 0.45 ne - ns 0.92 ns 0.29
CAT ne - ns 0.48 ns 0.62 ns 0.70 ns 0.80 ns 0.64
GPx ne - 3.39 0.003 - 0.33 0.02 - 0.54 0.03 - 0.55 0.001 - 10.16 0.004
GSH ns - ns 0.66 ns 0.48 ns 0.48 ns 0.89 ns 0.38
Lycopene - 31.59 0.044 ns 0.23 ns 0.75 ns 0.52 ns 0.20 ns 0.96
Lutein ns 0.67 ns 0.60 ns 0.82 ns 0.51 ns 0.47 ns 0.63
ns: non significant.
ne: non entered in this regression model.
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9(p < 0.05) with LDL-c (r = 0.38), HDL-c (r = -0.43), the
LDL/HDL index (r = 0.47), the TC/HDL index (r = 0.41)
and MDA (r = 0.54). SOD and CAT activities were corre-
lated with HDL-c (r = -0.34 and -0.48), the LDL/HDL
index (r = 0.31 and 0.42) and MDA (r = 0.49 and 0.45). In
addition, CAT was positively associated with the TC/HDL
index (r = 0.52). However, a positive association was
observed between GPx activity and HDL (r = 0.64), and a
negative association was observed between GPx activity
and LDL-c (r = -0.64), the LDL/HDL index (r = -0.72), the
TC/HDL index (r = -0.66) and MDA (r = -0.73).
The results of our analyses of carotenoids and total-
tocopherols (T-tocopherols) are summarized in Table 5.
There was no significant difference for lutein, zeaxanthin,
cryptoxanthin or b-carotene levels between the HD
group and the control group (p > 0.05). Moreover, both
alpha-carotene and lycopene levels were reduced by half
in the hemodialysis group compared with the control
group (p < 0.05). Additionally, Spearman’s correlation
showed that lycopene levels were negatively correlated
with MDA levels (r = -0.50; p < 0.01), LDL-c (r = -0.38;
p = 0.01) and the LDL-c/HDL-c index (r = -0.33; p =
0.03). Otherwise, this exogenous antioxidant was posi-
tively correlated with GPx activity (r = 0.30; p = 0.03).
Furthermore, significant associations (p < 0.05) between
lutein and LDL-c (r = -0.30), the LDL/HDL index (r =
-0.33) and MDA levels (r = -0.45) were observed.
Regression models (Table 1) were performed based on
the significant correlations obtained among exogenous
and endogenous antioxidants and the lipid profile and
the lipid peroxidation product (MDA). The total choles-
terol and triglyceride levels were not associated with
other biochemical parameters or with exogenous or
endogenous antioxidants except GPx activity. Addition-
ally, hematological and renal biomarkers were entered in
these models as co-variables, and they did not influence
Table 2 Hematological and biochemical analysis
Parameters Healthy Subjects (n = 20) Hemodialysis Patients (n = 29) Reference Values
57
Men (n = 10) Women (n = 10) Men (n = 19) Women (n = 10) Men Women
Hemoglobin (g.dL
-1) 14.90 ± 0.50 9.92 ± 0.29
a, c
16.5 ± 0.4 12.8 ± 0.1 10.0 ± 0.4
c 9.7 ± 0.5
c 12 - 18 11 - 16
Hematocrit (%) 43.20 ± 1.20 30.54 ± 4.73
a, c
46.9 ± 0.8 38.0 ± 0.8 30.8 ± 1.2
c 29.8 ± 1.4
c 39 - 53 35 - 47
Albumin (g.dL
-1) 3.98 ± 0.06 3.15 ± 0.03
a, c 3.4 - 5.0
4.02 ± 0.1 3.9 ± 0.05 3.2 ± 0.03
c 3.1 ± 0.05
c
Creatinine (mg. dL
-1) 0.68 ± 0.07 10.17 ± 0.62
a, b 0.8 - 1.3
0.89 ± 0.06 0.39 ± 0.03 11.5 ± 0.08 8.40 ± 0.83
Urea (mg. dL
-1) 27.40 ± 1.60 164.55 ± 7.46
a, b 15 - 39
28.96 ± 2.55 25.29 ± 1.36 171.10 ± 10.10 160.21 ± 11.73
The values are expressed as mean ± standard error of the mean (SEM).
a p < 0.05 when compared with healthy subjects;
b Inter gender difference (p < 0.05);
c Below to reference value.
Table 3 Lipid profile results of studied groups and reference values
Parameters Healthy Subjects (n = 20) Hemodialysis Patients (n = 29) Reference Values
57
Men (n = 10) Women (n = 10) Men (n = 19) Women (n = 10) Men Women
TC (mg.dL
-1) 147.27 ± 4.48 181.14 ± 5.38
a < 200
145.9 ± 7.9 148.9 ± 4.1 178.2 ± 6.2 182.7 ± 10.3
LDL-c (mg.dL
-1) 72.66 ± 4.37 115.89 ± 3.79
a < 130
69.4 ± 6.5 76.9 ± 5.6 117.5 ± 4.5 111.5 ± 7.0
HDL-c (mg.dL
-1) 55.90 ± 3.00 28.89 ± 1.92
a
53.0 ± 3.9 61.0 ± 3.9 29.2 ± 2.9 28.7 ± 2.4 > 40 > 45
TG (mg.dL
-1) 90.70 ± 6.40 160.37 ± 9.28
a < 150
90.7 ± 6.3 85.4 ± 11.0 175.4 ± 11.9 131.9 ± 11.7
b
LDL-c/HDL-c 1.28 ± 0.11 4.48 ± 0.32
a < 3.55
1.3 ± 0.1 1.2 ± 0.2 4.7 ± 0.5 4.0 ± 0.2
TC/HDL-c 2.68 ± 0.15 7.12 ± 0.55
a <5
2.8 ± 0.2 2.5 ± 0.3 7.3 ± 0.9 6.8 ± 0.6
b
The values are expressed as mean ± standard error of the mean (SEM).
a p < 0.05 when compared with healthy subjects;
b Inter gender difference (p < 0.05).
Abbreviations: TC: cholesterol total; LDL-c: LDL cholesterol; HDL-c: HDL cholesterol; TG: triglycerides.
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lycopene levels were inversely associated with the LDL-c
and HDL-c levels and were positively associated with
GPx activity. On the other hand, a negative association
was found between GPx activity and MDA levels. More-
over, the GPx activity was a significant variable in the
regression models for the TC/HDL-c and LDL-c/HDL-c
indexes.
Discussion
Cardiovascular diseases play an important role in the
mortality of HD patients, and we observed that all HD
patient deaths that occurred during the study were due
to vascular diseases. The pathogenesis of atherosclerotic
ischemic heart disease resulted, in part, from the over-
production of reactive species of oxygen and nitrogen.
Furthermore, HD process is associated with impairment
of the antioxidant defense mechanisms, which is one of
the main factors that contributes to cardiovascular dis-
ease and is a significant cause of morbidity and mortal-
ity in these patients [22].
Therefore, it is of particular interest to explore the
possible associations among oxidative stress biomarkers,
exogenous antioxidants, such as vitamins, and, espe-
cially, the carotenoids, the lipid profile and the risk of
cardiovascular disease in HD patients.
In the present study, HD patients showed a moderate
increase in triglycerides and total and LDL cholesterol
Table 4 Results of studied groups: antioxidants and lipid peroxidation biomarker
Biomarkers Healthy Subjects (n = 20) Hemodialysis Patients (n = 29)
Men (n = 10) Women (n = 10) Men (n = 19) Women (n = 10)
GSH (μmol.g/Hb) 6.03 ± 0.26 7.87 ± 0.27
a
5.6 ± 0.2 6.5 ± 0.4 7.8 ± 0.4 7.9 ± 0.4
CAT (K/mg Hb) 27.96 ± 4.18 56.99 ± 4.25
a
26.6 ± 6.9 29.3 ± 5.2 55.5 ± 5.5 61.1 ± 7.5
GPx 11.57 ± 0.39 6.61 ± 0.21
a
(μmol NADPH.min/g Hb) 12.2 ± 0.5 11.0 ± 0.5 6.5 ± 0.3 7.0 ± 0.3
SOD (U SOD/mg Hb) 0.69 ± 0.49 0.91 ± 0.03
a
0.6 ± 0.04 0.8 ± 0.07 0.9 ± 0.05 0.9 ± 0.05
MDA (μmol/L) 4.53 ± 0.16 6.92 ± 0.36
a
4.3 ± 0.2 4.8 ± 0.3 7.4 ± 0.6 6.1 ± 0.2
The values represent the mean ± standard error of the mean (SEM).
a p < 0.05 when compared with healthy subjects.
Abbreviations: GSH: reduced glutathione; CAT: catalase activity; GPX: glutathione peroxidase activity;
SOD: superoxide dismutase activity; MDA: malondialdehyde.
Table 5 Results of vitamin levels analyzed in plasma of subjects studied
Vitamins Healthy Subjects (n = 20) Hemodialysis Patients (n = 29)
Men (n = 10) Women (n = 10) Men (n = 19) Women (n = 10)
Lutein 0.62 ± 0.06 0.46 ± 0.05
0.5 ± 0.05 0.7 ± 0.1 0.5 ± 0.08 0.5 ± 0.05
Zeaxanthin 0.08 ± 0.01 0.07 ± 0.01
0.07 ± 0.004 0.1 ± 0.01 0.07 ± 0.008 0.07 ± 0.005
Criptoxanthin 0.18 ± 0.07 0.21 ± 0.04
0.1 ± 0.02 0.2 ± 0.1 0.1 ± 0.03 0.3 ± 0.09
a-Carotene 0.18 ± 0.03 0.07 ± 0.01
a
0.08 ± 0.01 0.3 ± 0.05
b 0.07 ± 0.008 0.09 ± 0.01
b-Carotene 0.64 ± 0.09 0.50 ± 0.07
0.4 ± 0.05 0.9 ± 0.1
b 0.4 ± 0.03 0.7 ± 0.2
b
Lycopene 0.64 ± 0.06 0.35 ± 0.05
a
0.6 ± 0.06 0.7 ± 0.1 0.3 ± 0.06 0.4 ± 0.1
T-Tocopherols 29.6 ± 1.3 33.2 ± 1.9
29.8 ± 2.0 29.4 ± 1.8 29.4 ± 1.7 41 ± 3.4
b
The values represent the mean ± standard error of the mean (SEM).
The unit for all parameters is μmol.L
-1.
a p < 0.05 when compared with healthy subjects.
b Inter-gender difference (p < 0.05).
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lipoprotein (HDL) cholesterol, and these findings were
in accordance with those of other authors [23]. The ele-
vated levels of LDL cholesterol may provide increased
substrates for reactive oxygen species. These free radi-
cals react with the low-density lipoprotein (LDL), lead-
ing to the formation of oxidized LDL particles, which
are important in the initiation and progression of ather-
osclerotic plaques because they can elicit inflammatory
processes and lipid accumulation within the arterial wall
[24]. In addition, Kinosian et al. [25] has reported that
the LDL-c/HDL-c and TC/HDL-c indexes are more reli-
able for assessing the risks for atherogenic diseases than
the lipid profile comprised of isolated parameters. The
atherogenic risks, including the LDL/HDL and TC/HDL
indexes, were elevated in HD patients, suggesting that
metabolic abnormalities are present in HD patients that
can contribute to cardiovascular disease.
In accordance with previous studies [26,27], HD
patients present a vulnerability to oxidative species that
is evidenced by elevated levels of MDA. Lipid peroxida-
tion is thought to be the main factor influencing athero-
genesis [28,29]. Moreover, the multivariate analysis
demonstrated that the increase of lipid peroxidation was
negatively correlated with GPx activity deficiency,
demonstrating that ROS generation can contribute to
decreased GPx activity.
The results of this study indicate that patients who
periodically perform hemodialysis undergo changes to
their endogenous antioxidant system. A major finding
was the decrease of GPx activity, which was reduced by
almost 50 percent in HD patients compared to controls.
This decrease in GPx activity may represent an early
consequence of active nephron mass reduction, reinfor-
cing the suggestion that the renal tubule is the predomi-
nant site of synthesis of GPx [30]. Interestingly, urea
and creatinine levels were negatively correlated with
GPx activity. Thus, in HD patients, when renal impair-
ment is increased, GPx activity is lower, and, conse-
quently, there is a reduced ability to detoxify hydrogen
peroxide, as GPx is considered to be the primary
defense for elimination of these reactive species in ery-
throcytes [31].
In HD patients, the elevation of GSH levels did not seem
to be sufficient to protect against the lipid damage because
the GPx activity was decreased. It is known that GSH
levels are dependent on GPx activity to counter the oxida-
tive imbalance [8]. The GSH elevation in HD patients is
known to be a compensation mechanism [26,28,32]. Addi-
tionally, the regression models suggest that the elevation
of MDA, as well as increases in the TC/HDL and LDL/
HDL indexes, could be the most important of the factors
analyzed in this study that are associated with GPx defi-
ciency. By contrast, the antioxidant function of HDL-c, in
association with antioxidant enzymes [33], is observed to
be based on the positive relationship between this choles-
terol fraction and GPx activity. However, the lower levels
of HDL and GPx activity cannot counter the oxidative
[34-37] stress or the increase in atherogenic indexes.
Moreover, CAT and SOD activities were increased, as well
as the GSH levels, to compensate for the oxidative stress
that results from the hemodialysis process [30,38].
With respect to exogenous antioxidants, the antioxi-
dant and anti-inflammatory activity [8] of vitamin E (a-
and g-tocopherol) is known, and the vitamin E deficiency
in HD patients conflicts with previous results [39]. In this
work, the plasma vitamin E levels were not reduced HD
patients in comparison with controls, which is consistent
with previous studies where blood collection was per-
formed before hemodialysis treatment [40,41]. Moreover,
the levels of vitamin E were not associated with their
main function, which is to prevent lipid peroxidation
and, consequently, to prevent LDL oxidation [42,43].
However, this lack of association could be due to the fact
that we evaluated only MDA levels, and the specific LDL
oxidation product was not quantified.
The majority of the previous studies evaluated the total
carotenoids [44] or b-carotene [45]; in the present study,
we investigated the individual carotenoids. It is known
that carotenoids have an important role in the prevention
of human diseases, such as cataracts, cancer and other
d i s e a s e sa c t i n ga sa n t i o x i d a n t s[ 3 8 , 4 6 ] ,a sw e l la sh e a r t
protection in hemodialysis patients [47]. Usually, dialysis
patients have abnormal levels of vitamin and carotenoid
because of inadequate dietary intake resulting from poor
appetite, dietary restrictions and metabolic disorders
associated with renal failure [47,48]. In this study, the
HD patients only had lower levels of lycopene and a-car-
otene in comparison to controls. Several studies have
indicated that lycopene is an effective antioxidant and a
free radical scavenger because of the number of conju-
gated double bonds [46,49]. Lycopene has also been sug-
gested as a possible carcinogenesis and atherogenesis
prevention agent because it protects critical biomole-
cules, including lipids, low-density lipoproteins (LDL),
proteins and DNA [50]. Our results are consistent with
previous reports [30,51], which found that levels of lyco-
pene are reduced almost by half in HD patients com-
pared with healthy subjects. In 1994, Loughrey et al. [52]
demonstrated that macrophage enrichment with lyco-
pene or with a-carotene results in the suppression of cel-
lular cholesterol synthesis and an increase in macrophage
LDL receptor activity. This effect can lead to enhanced
clearance of LDL from the plasma. In this line, the multi-
variate analysis conducted here demonstrated an inverse
association of lycopene levels and LDL-c levels, suggest-
ing that lycopene could be considered an important
extrinsic factor for the prevention of atherosclerosis,
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Page 7 of 9which is consistent with the findings of Rissanen et al.,
2002 [53]. In addition to a probable protective effect of
lycopene, these results demonstrated a lack of association
with gender or age.
In the present study, we found that a-carotene levels
were higher in the control group compared with healthy
subjects in a Canadian study [51]. This could be due to
interregional variations in diet. Levels of b-carotene,
lutein, zeaxanthin and b-cryptoxanthin showed no sig-
nificant differences between the studied groups. Levels
of b-cryptoxanthin and b-carotene were consistent with
those reported by Sundl et al. 2009 [51]. Moreover, an
influence of gender on the levels of these carotenoids
was also observed in another study, which reported that
the values were higher in women than in men [54].
Interestingly, there are studies that report the existence
of the reference values for different populations [55].
Our results are similar to those obtained in a Spanish
population [56]; however, in this population, inter-gen-
der variation was not observed. With respect to zeax-
anthin and lutein levels, our results are consistent with
those of previous reports [51,54].
Thus, our results demonstrated that GPx, an endogen-
ous antioxidant with an important function in renal tis-
sue, influenced lipid damage.I m p o r t a n t l y ,l y c o p e n e ,a n
exogenous antioxidant, may modulate lipid profile dis-
turbance and, potentially, be protective against athero-
sclerosis in HD patients. Subject age did not influence
the evaluated indexes of cardiovascular risk or the mar-
kers of oxidative stress and vitamins. However, gender
was found to influence triglycerides and the total choles-
terol/HDL-c index.
Conclusions
We showed that hemodialysis patients had reduced of
lycopene levels and GPx enzyme activity which were asso-
ciated with an increase in lipid damage that was evident
based on increased lipid peroxidation and decreased HDL-
c levels. It was demonstrated that the HD patients have
higher index values for atherogenic risk. Thus, the decline
of important exogenous (lycopene) and endogenous (GPx
activity) antioxidants associated with the lipid profile
could directly influence morbidity and mortality in these
patients. However, more studies are required to verify
whether it is possible to increase lycopene levels through
diet, and the likely role of decreased GPx activity in car-
diac risk and atherogenesis in this group of patients should
be further investigated.
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